Executive Summary: A Digital Leap in Vascular Care
Essex Partnership University NHS Foundation Trust (EPUT) has announced a significant advancement in its clinical capabilities with the integration of cutting-edge digital technology designed to revolutionize the management of leg ulcers and non-healing wounds. By adopting the "BlueDop" system, the Trust is moving away from traditional, often uncomfortable diagnostic methods toward a more agile, data-driven approach.
This shift represents a broader commitment by the Trust to leverage digital transformation to improve patient outcomes, reduce clinical bottlenecks, and enhance the overall experience for those suffering from complex lower-limb vascular conditions. While the Trust navigates challenges related to its larger Electronic Patient Record (EPR) infrastructure, this localized success story underscores the immediate, tangible benefits of targeted digital health investment.
The Clinical Challenge: The Burden of Traditional Wound Assessment
For years, the gold standard for assessing lower limb vascular health involved ultrasound-based techniques that, while effective, presented significant patient-centric drawbacks. Patients requiring these assessments were often forced to remain in a supine, flat position for up to 30 minutes.
The procedure required the application of tight, blood-pressure-style cuffs around the limbs to measure arterial pressure. For many patients—particularly the elderly or those with chronic pain—this process was a source of profound physical discomfort, distress, and anxiety. Furthermore, the time-intensive nature of these assessments created clinical backlogs, limiting the number of patients that could be treated within a single shift.
The Tissue Viability Service at EPUT, which provides specialist assessment and support for patients across southeast Essex, identified these diagnostic hurdles as a primary area for improvement. The goal was to find a solution that offered high-fidelity clinical data while prioritizing patient dignity and comfort.
The Technological Solution: The BlueDop Integration
The solution arrived in the form of BlueDop, a portable, wireless Doppler probe technology supplied by BlueDop Medical. This device marks a paradigm shift in how clinicians assess vascular impairment.
How the Technology Works
The BlueDop system consists of a wireless Doppler probe that communicates directly with a tablet interface. Unlike traditional ultrasound, which requires stationary, bulky equipment, the BlueDop system is compact and portable. It allows clinicians to acquire a comprehensive picture of a patient’s blood circulation in a fraction of the time previously required.
By providing real-time data, the system allows the Tissue Viability Service to plan the next steps in a patient’s care journey almost immediately. This rapid diagnostic capability is critical; in wound care, time is a significant factor in preventing infection and accelerating healing.
Impact on Clinical Practice
Holly May, a leg ulcer nurse specialist at EPUT, has been at the forefront of this implementation. According to May, the kits are a "big step forward" for the department.
"It enables us to get a full picture of a patient’s blood circulation and any impairments quickly so we can provide effective treatment, which means the patient can recover quicker," May explained. "As well as providing a quicker and more efficient way to treat patients, this innovative technology has reduced anxiety for some patients needing these assessments and made them more comfortable."
The feedback from the patient community has been overwhelmingly positive. By removing the need for prolonged periods of immobilization and painful cuff application, the Trust has successfully humanized a routine but necessary medical procedure.
Chronology of Digital Transformation at EPUT
The deployment of BlueDop is one of many initiatives currently underway within the Trust’s digital roadmap. To understand the current landscape, it is necessary to examine the timeline of EPUT’s wider digital efforts:
- 2023–2024: Identification of Clinical Gaps: The Trust identifies vascular care as a priority for digital intervention due to high patient demand and the limitations of legacy diagnostic tools.
- Early 2025: Procurement and Pilot Testing: EPUT evaluates various portable Doppler solutions, eventually selecting BlueDop for its ease of use and integration potential.
- Late 2025: Deployment: The rollout of BlueDop kits across the southeast Essex Tissue Viability Service begins.
- February 2026: EPR Strategy Review: EPUT and the Mid and South Essex NHS Foundation Trust acknowledge that the "Nova" EPR programme—a massive, trust-wide digital infrastructure project—requires a revised timeline due to complexity.
- 2027 (Projected): Phased go-live of the Oracle Health-supported "Nova" EPR system.
Supporting Data and Strategic Context
The implementation of small-scale, high-impact digital tools like BlueDop is a deliberate strategy to demonstrate value while the Trust works on its larger-scale digital infrastructure.
The "Nova" EPR Programme
While BlueDop represents a success in departmental-level innovation, the Trust’s overarching digital strategy is tethered to the "Nova" programme. Nova is a joint venture between EPUT and the Mid and South Essex NHS Foundation Trust to implement a unified Electronic Patient Record (EPR) system, supplied by Oracle Health.
The project is designed to align physical and mental health care provision across the two trusts, creating a single source of truth for patient data. However, such large-scale digital transformations are rarely without friction.
Challenges in Scaling Digital Health
In February 2026, it was confirmed that the Nova programme, originally slated for a phased launch starting in winter 2026, would face delays. Zephan Trent, the Executive Director of Digital, Transformation and Strategy at EPUT, addressed these challenges in a board paper dated February 4, 2026.
Trent noted that while the programme is "progressing," there are significant risks linked to "system integration and programme complexity." This transparency is a hallmark of modern NHS digital leadership, acknowledging that the complexity of aligning mental and physical health records across a large geographic area requires meticulous attention.
Official Responses and Strategic Outlook
The Trust’s leadership remains committed to both the macro-level ERP integration and the micro-level clinical improvements.
The Stance on Nova
Addressing the delay, Zephan Trent confirmed that Oracle Health has committed to no additional costs associated with the schedule change, though the Trust is currently reviewing the requirement for extra resourcing to manage the transition. The phased approach is now firmly scheduled for 2027.
The strategy is to ensure that when the system goes live, it is stable and capable of handling the high-volume data streams generated by the Trust’s various services, including the newly digitized Tissue Viability Service.
The Role of Localized Innovation
The success of the BlueDop deployment serves as a "proof of concept" for EPUT’s broader digital ambitions. By showcasing how digital tools can directly benefit the patient—reducing their time in the clinic, lowering their stress levels, and improving clinical outcomes—the Trust is building a culture of digital literacy and adoption among its staff.
Holly May’s sentiment—that the technology demonstrates the tangible impact of digital innovation on patient care—is echoed across the Trust. For clinicians, the ability to see immediate results and receive positive feedback from patients is a powerful motivator to continue embracing new technologies, even as the Trust navigates the complexities of larger-scale systemic changes.
Implications for the Future of NHS Care
The experience of Essex Partnership University NHS Foundation Trust offers three key takeaways for the wider NHS digital landscape:
- Patient-Centricity as a Driver for Innovation: Technologies that solve immediate pain points for patients (like the discomfort of traditional Doppler tests) gain faster adoption and provide immediate value.
- The Necessity of Phased Digital Adoption: While large ERP systems are essential for long-term health system integration, they are prone to complexity-related delays. Managing these alongside smaller, "quick-win" digital projects helps maintain morale and continuous service improvement.
- Transparency in Governance: The willingness of EPUT leadership to report openly on the risks and delays of the Nova project fosters trust among stakeholders and allows for more realistic resource planning.
As EPUT continues its journey toward a more digital-first model of care, the integration of tools like BlueDop ensures that clinical staff remain focused on what matters most: the patient. Whether through a high-tech EPR system or a handheld Doppler probe, the objective remains the same—to provide the right care, at the right time, with the highest level of comfort and efficiency.
With the 2027 rollout of the Nova system on the horizon, the Trust is well-positioned to integrate these departmental innovations into a unified, robust, and highly efficient healthcare network. The current successes in southeast Essex provide a clear roadmap for how clinical services can bridge the gap between legacy care and the future of digital medicine.
